Quanome Technologies is a Nevada holding company that spent the last year exiting a subscale United States logistics franchise, concentrating on a Hubei pharmaceutical distributor, and then renaming itself as a quantum-technology platform. The late-summer ticker change and the later announcement of a Global Quantum Council sit on top of a business that still earns its keep by moving infusion products through Chinese hospital agents. The March quarter printed a small consolidated profit only because the sale of American Bear Logistics produced a multi-million disposal gain. Continuing operations remained deeply loss-making, and the quantum story has not yet appeared as a revenue line.
Cash finished the March quarter at $1 million. Continuing operations used $3 million of operating cash across the first nine months of the fiscal year, which is why management wrote an explicit going-concern warning into the interim statements. The largest asset is an unsecured loan to a single third party carried at more than $8 million after a credit-loss reserve. Hupan Pharmaceutical grew several-fold from a tiny year-ago base, yet selling and administrative costs still exceed gross profit. That mix is the real company underneath the new name.
The investment debate is whether the China distributor can fund itself and whether that loan is collectible before the Nasdaq bid-price clock and a baby-shelf registration force more equity into a sub-dollar quote. A staffed quantum franchise with signed commercial work would change the residual claim. An advisory network without contracts would leave shareholders holding a going-concern distributor plus a marketing identity. Mid-September trading near fifty-six cents, after a session that printed above a dollar on heavy volume, prices the narrative more than the cash engine.